Skip to main content

Full text of "USPTO Patents Application 10002961"

See other formats


21. (New) A system according to claim 1 wherein said biocompatible chemical gradient 
stabilizing gel medium is agarose. 

22. (New) A system according to claim 1 wherein said chemical attractant is a member 
selected from the group consisting of folic acid, guinea pig serum, activated complement, bacterial 
peptides and mammalian chemokines 

23. (New) A system according to claim 21 wherein said chemical attractant is folic acid. 

REMARKS 

Claims 1-7 are under consideration in this application. Claims 1 and 4 have been amended and 
claims 2, 3 and 5-7 remain as originally presented. New claims 21-23 have been added. No new matter 
has been introduced. 

The applicants' invention is directed to a system for monitoring the effect of extra-cellular 
chemical stimuli on the translational motion of cells, the system comprising: (a) an array of one 
or more cell containment wells; (b) an array of one or more chemical attractant wells 
interspersed among the array of one or more cell containment wells; (c) one or more 
substantially planar sensing electrodes distributed within the arrays of cell containment wells and 
chemical attractant wells so that at least one of the sensing electrodes is between one cell 
containment well and one chemical attractant well, wherein the one or more sensing electrodes is 
operatively coupled to a sensing device capable of measuring an electrical parameter of the 
sensing electrode; (d) at least one counter electrode in electrical connection with the one or more 
sensing electrodes; and (e) a biocompatible chemical gradient gel stabilizing medium in 
simultaneous diffusional contact with the arrays of cell containment wells and chemical 
attractant wells. 

As originally drafted the claims used the term 'Volume(s)" which has been replaced by 
well(s) for containing cells and/or chemical attractant. The term "attractant" has been substituted 
for agent as originally used. It is noted that volume(s) and well(s) are used interchangeably in 
the specification. (See for example, page 14, line 17 and page 23, lines 12, 19, 27 and 32.) The 
same is true for the term "chemical attractant'' as now used in the claim for replacing chemical 
agent. (See for example, page 12, lines 13 and 16, page 14, lines 20 and 24, page 18, lines 12 and 
1 8, page 23, lines 7, 1 3 and 32 and page 26, lines 6, 1 5 and 3 1 .) 

The Hxaminer has rejected claim 1-7 under 35 U.S.C. 1 12 as being indefinite for the broad term 
"chemical agent volume". As noted above, this term has been replaced by chemical attractant well for 

-3- 



which there is more then adequate support. It is further noted that the specification contains multiple 
examples of chemical attractants, including folic acid, guinea pig serum, activated complement, bacterial 
peptides and mammalian chemokines (page 9, 3rd full paragraph and page 18, 1st full paragraph. 

The term ''chemical agent volume'"* (replaced by chemical attractant well) can be defined 
as the chemoattractant- containing well that is the originating point for diffusion of chemical 
agents that will influence (either positively or negatively) the movement of cells in a directional 
manner. Likewise, the "cell containment well" is the originating point for migrating cells that 
will respond to the chemoattractant. The volume of the chemoattractant-containing well and the 
cell-containing wells is small in relation to the volume of the culture system. In the 
demonstrated use, these volumes are 2 to 3% of the total volume of the '^biocompatible chemical 
gradient gel stabilizing medium". In the example provided, ''chemical attractant well" and the 
"cell containment w^ell" are wells cut in an agarose gel as one form of "biocompatible chemical 
gradient gel stabilizing medium". For example, the wells that are formed to hold 
chemoattractant and cells at the initiation of the assay are usually 1.5 mm in diameter and 5 mm 
in depth, and contain a volume of approximately 5 to 10 microliters. In the invention, the cells 
are induced to move across the sensing electrode that has been placed in the path of the moving 
cells. 

The Examiner has also rejected the claims in that the term "biocompatable chemical 
gradient stabilizing medium" is too broad. This term has been amended to read biocompatible 
chemical gradient gel stabilizing medium. This gel is preferably agarose. The gel ser\ es as a 
matrix that allows for the gradient formation by the diffusing chemical attractant. The art is 
familiar with other such media which include in addition to agarose, polyacrylamide, collagen or 
other gels. The Examiner is correct that in the case of the agarose gel, the term "biocompatible 
chemical gradient stabilizing medium" means that cells migrate in and under an agarose 
environment. 

The Examiner has rejected claims 1-7 as obvious (35 U.S.C. 103(a)) over Griaever et al. 

in view of Nelson et al. It is the Examiner's position that Giaever et al. teach a device for 

monitoring the activities of living cells in tissue culture using electronic means that Giaever's 

device comprises a cell culture, wherein chemical agents are contained within the cell culture 

and wherein electronics are connected to arrays of electrodes contained within the cell culture, 

the electronic connected to the electrodes within the cell culture also containing chemical agents 

to monitor the activities of the living cells in tissue culture. The Examiner expressly 

-4- 



acknowledges that Giaever et al. "do not expressly teach all the different types of chemical 
agents contained within the cell culture, a biocompatible chemical gradient stabilizing medium 
that is in simultaneous diffusional contact with the arrays of cell containment volumes and 
chemical agent volumes and all the systems selected parts." It is the Examiner's position 
however that Nelson et al. supplies the omitted elements. 

Giaever et al. are directed to monitoring the activities of cells grown in tissue culture. In 
Giaever et al., electrodes are deposited by vacuum evaporation in two layers at the bottom of a 
tissue culture enclosure. AC current of about one microamp and fixed or varying frequencies is 
applied between a large counter electrode and a small active electrode, while the voltage is 
monitored with a phase sensitive detector. As a two probe measurement is involved, the active 
electrode is made small, such that its impedance dominates the measurement. Cells are cultured 
directly on the small electrodes. As they attach and spread (flatten out) on the electrode surface 
they cause large changes in electrical impedance of the system. These changes are highly 
dependent on the type of protein initially absorbed on the electrode surface. The following 
attachment and spreading cell motion causes cell contacts with the electrode to change with time, 
and this in turn causes fluctuations in the electrode's impedance. 

Giaever et al. do not teach or suggest a manner of measurement that could detect the 
arrival of cells at a detecting electrode, nor do they indicate the use of stabilizing matrix to 
sustain gradient formation. There is nothing in Giaever et al. to suggest that a non-liquid matrix 
such as an agarose gel (the "biocompatible chemical gradient stabilizing medium'') would be 
compatible with the sensitive electronic measurements that are made in accordance with the 
instant invention, that such measurements would be possible. In fact, as acknow^ledged by the 
Examiner, there is no indication that a matrix would be compatible wath the electronic 
measurements contemplated. 

In addition, Giaever et al. describe cells that have been deposited directly on the 
electrode, and do not describe the measurement of movement by cells from a distance to the 
measuring electrode. 

Nelson et al represents the state of the art prior to the instant invention and has been 
acknowledged as such by the applicants at page 4 of the application. The applicants describe the 
Nelson assay and conclude with its disadvantages noting that the migration patterns of the cells 
arc obser\'ed optically and that they have to be done at many points to get an estimate of the 

-5- 



extent of movement in each assay and that in addition the nature of the measurements obtained 
render it very difficult to quantify the rate at which the cells move in response to chemotactic 
stimuli. 

There is no indication in Nelson et al. that any other measurement technique could be 
used other than visual detection. With the visual detection scheme described by Nelson et al., it 
would not be possible to carry out multiple simultaneous detection of independent chemotactic 
responses, and the larger the scale, the more complex this problem would become. Moreover, 
the visual detection method does not allow for the undisturbed monitoring of cell behavior. For 
example, exposure of cells to illuminating light for microscopy can disturb normal patterns of 
cell function. The Nelson et al. method is an endpoint assay system: the assay concludes at a 
fixed point of time, and measurements are taken that prevent the ongoing assessment of the cells 
(e.g. the cells are fixed and stained at the conclusion of the assay). In accordance with the 
invention, the measurements are carried out continuously in near-real time, and can be carried 
out for several days, allowing for the measurement of slow chemotactic responses. 

It is submitted that the skilled artisan would not, contrary to the Examiner's assertion, "be 
motivated to modify Giaever et al's device to include Nelson's teachings for an improved benefit 
of producing the instantly claimed device of monitoring the activities of cells. 

What the Examiner has done is to read back into the prior art the teachings of the 
invention which came later. 

The U.S. Supreme Court has cautioned against ''slipping into the use of hindsight" and 
urged courts ''to resist the temptation to read into the prior art the teachings of the invention in 
issue." Graham v. John Deere Co., 383 U.S. 1, 36, 148 USPQ 459, 474 (1966). For example, 
impermissible "hindsight" is using knowledge of the solution to determine that the answer to the 
technical problem was "obvious", whereas to one without knowledge of the solution, the answer 
was not "obvious" at all. 

The impermissible use of hindsight is to combine pieces of the prior art to argue that a 
combination invention is obvious. There must be something in the prior art that suggested the 
combination of these particular prior art devices and processes other than the hindsight gained 
from knowing that the inventor chose to combine these particular things in this particular way. 
Uniroyal, Inc. v. Rmlkin-Wiley Corp.. 837 F.2d 1044, 10151,5 USPQ2d 1 1434, 1438 (Fed. Cir. 
1988). 

-6- 



The applicants' device, once disclosed seems obvious and simple. The test is whether the 
subject matter of the claimed inventions would have been obvious to one skilled in the art at the 
time the inventions were made, not what would be obvious after reading the patents in suit. 
Panduit Corp. v. Dennison Mfg. Co., 11 A F.2d 1082, 1090-002, 227 USPQ 337, 342-43 (Fed. 



The Examiner has stated that one of ordinary skill would have been motivated to modify 
Giaever et al. in view of the Nelson teachings. However, various bits of data or teachings of the 
prior art are not properly combined unless there is something in the prior art itself that suggests 
that those teachings could or should be combined. Both the suggestion for combining teachings 
to make the invention and its reasonable likelihood of success ''must be founded in the prior art, 
not in the applicant's disclosure." In re Dow Chem,, 837 F.2d 469, 473,5 USPQ2d 1529, 1 1531 
(Fed. Cir. 1988). ''Motivated to modify" without more does not meet the test that the invention 
was obvious. 

In this regard, it is pointed out that Nelson et al. was available prior art since 1975 and 
that in spite of the activity, i.e., tissue culture is an indispensable research tool. In addition, it has 
played an essential role in the development of modem biotechnology. Some of the powerful new^ 
applications are: pharmaceuticals, monoclonal antibodies, vaccines, genetic screening, skin 
grafts, gene therapy and in vitro toxicology, yet the applicants are the first to propose the 
instantly claimed method and assay. 

In view of the above, reconsideration and allowance of the claims in the application are 
respectfully requested. 



Cir. 1985). 



Respectfully submitted. 




Evelyn M. SWnmer, Reg. No. 19,603 
Cummings & Lockwood 
P. O. Box 1960 
New Haven, CT 06509-1960 
Tele: (203)351-4229 



.StmLibl : 1026 989 . 1 08/2 1/03